Paratek Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch PRTK and buy or sell other stocks, ETFs, and their options commission-free!

About PRTK

Paratek Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI), and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. 

CEO
Evan Loh, MD
CEOEvan Loh, MD
Employees
Employees
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1996
Founded1996
Employees
Employees

PRTK Key Statistics

Market cap
127.83M
Market cap127.83M
Price-Earnings ratio
-2.00
Price-Earnings ratio-2.00
Dividend yield
Dividend yield
Average volume
1.55M
Average volume1.55M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$3.65
52 Week high$3.65
52 Week low
$1.29
52 Week low$1.29
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.